ImageneBio, Inc.
IMA · XNASCIK 1835579fmd_13CCQ73QYJQ685Z6T4MKR7TBK9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 9 | 31 | 16 | 9 | 4 | 1 |
| Research and development | 45 | 47 | 64 | 60 | 32 | 29 |
| Gain on sale of real estate | – | – | (0) | (0) | – | – |
| Total operating expenses | 54 | 65 | 87 | 85 | 41 | 49 |
| Compensation and benefits | – | – | – | – | 3 | 5 |
| Operating income | (45) | (34) | (71) | (75) | (37) | (48) |
| Interest expense | – | – | – | – | 0 | 0 |
| Interest and investment income | – | 0 | 2 | 7 | – | – |
| Other non-operating income (expense) | 0 | 0 | 2 | 7 | 0 | 3 |
| Income before taxes | – | – | (69) | (68) | (37) | (46) |
| Income tax expense | – | 0 | 0 | (0) | 0 | (0) |
| Net income from continuing operations | – | – | (69) | (68) | (37) | (45) |
| Net income | (44) | (34) | (69) | (68) | (37) | (45) |
| Net income to common shareholders | – | – | – | – | (48) | (52) |